Printer Friendly

IMMUNOGEN, INC. NAMES JOHN A. KNOX DIRECTOR OF HUMAN RESOURCES

 CAMBRIDGE, Mass., June 9 /PRNewswire/ -- ImmunoGen, Inc. (NASDAQ: IMGN) today announced the appointment of John A. Knox as director, human resources, a newly created position. From 1991 to the present, Knox was director of Human Resources for Procept, Inc., a Cambridge, Mass., biotechnology company.
 "We are especially pleased to have Jack Knox join ImmunoGen at this stage of our development," states Donald J. McCarren, president and chief operating officer. "Our lead products, Oncolysin(R) B and Oncolysin S, are moving smartly through clinical trials and toward the market, and we appreciate the excellent contributions made by our employees to date. We also recognize that to ensure commercial success we must continue to recruit and retain exceptional individuals. Jack Knox is an experienced human resources professional who will be a key contributor to this process and to our management team as we meet the challenge of well-managed growth."
 Prior to his tenure at Procept, Knox was director of human resources at Park Cardiographics, a 500-employee, Mass.-based health-care firm and was director of human resources at Superior Brands. From 1986-1989, he was vice president of human resources and insurance at Seragen, a Mass. biotechnology company. Knox was director of corporate administration at Tech/Ops from 1981-1986 and, before that, was manager of personnel and administration at Autex Systems. He was a contract administrator for Raytheon Company from 1968-1972.
 Knox received an M.B.A. from Babson College, Wellesley, Mass., and a B.A. from the University of New Hampshire in Durham. He is a member of the Associated Industries of Massachusetts Human Resource Council, the Northeast Human Resource Association and the Massachusetts Biotechnology Council.
 ImmunoGen, Inc. develops innovative therapeutics for the treatment of cancer and immune-mediated diseases. The company produces proprietary toxins and drugs conjugated to highly specific targeting agents which search out and destroy cancer cells. The company's first- generation products, the Oncolysins, are designed for use in patients with residual disease following conventional therapy.
 -0- 6/9/93
 /CONTACT: Mark Ratner, director of external communications for ImmonGen, Inc., 617-661-9312/
 (IMGN)


CO: ImmunoGen Incorporated ST: Massachusetts IN: MTC SU: PER

CM -- NE002 -- 6865 06/09/93 08:31 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 9, 1993
Words:359
Previous Article:GE PLASTICS PURCHASES COMMERCIAL OPERATION OF ABS BUSINESS OF MEXICO'S INDUSTRIAS RESISTOL S.A.
Next Article:IMMUNOGEN, INC. NAMES ROBERT J. CONNAUGHTON, JR., GENERAL COUNSEL
Topics:


Related Articles
IMMUNOGEN EXPANDS MANAGEMENT TEAM: DONALD J. MCCARREN NAMED PRESIDENT AND CHIEF OPERATING OFFICER
IMMUNOGEN, INC. NAMES DIXIE ESSELTINE, M.D., DIRECTOR OF ONCOLOGY
IMMUNOGEN, INC. NAMES ROBERT E. TELLIS VICE PRESIDENT OF CORPORATE DEVELOPMENT
IMMUNOGEN, INC. NAMES CAROL A. GLOFF VICE PRESIDENT OF REGULATORY AFFAIRS
IMMUNOGEN ANNOUNCES RESIGNATION OF PRESIDENT DONALD J. McCARREN
IMMUNOGEN, INC., PROMOTES TWO IN RESEARCH AND DEVELOPMENT AND ANNOUNCES THE RESIGNATION OF ITS VICE PRESIDENT, CORPORATE DEVELOPMENT
IMMUNOGEN PROMOTES DIXIE ESSELTINE, M.D., TO VICE PRESIDENT, MEDICAL AFFAIRS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters